Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy ‐ short term (up to 12 weeks) compared with QUETIAPINE (very low certainty).
1 finding from 1 review
Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of PANSS score < 40%, decreased rate of BPRS score < 40% · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes clinically important response (defined by study) ‐ short term (up to… compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes adverse effects: Extrapyramidal effects ‐ akathisia ‐ short term (up… compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early: inefficacy ‐ short term (up to 12 weeks) compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Adverse effects: Extrapyramidal effects ‐ concomitant anticholinergic medication ‐ short term (up to 12 weeks) Participants requiring concomitant anticholinergic medication · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes adverse effects: Extrapyramidal effects ‐ concomitant… compared with AMISULPRIDE (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ any reason ‐ short term (up to 12 weeks) compared with AMISULPRIDE (very low certainty).
1 finding from 1 review
Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of BPRS score < 20% · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes clinically important response (defined by study) ‐ short term (up to… compared with RISPERIDONE (very low certainty).
1 finding from 1 review
Short‐term complications Number of women with at least one short‐term complication · women having reconstructive breast surgery
It is very uncertain whether PVP‐hydrogel‐filled changes short‐term complications Number of women with at least one… compared with saline‐filled implants (very low certainty).
1 finding from 1 review
Short‐term complications Number of women with at least one short‐term complication · women having reconstructive breast surgery
It is very uncertain whether anatomical changes short‐term complications Number of women with at least one… compared with round implants (very low certainty).
1 finding from 1 review
Short‐term remission · adults with panic disorder
It is very uncertain whether cognitive behaviour therapy changes short‐term remission ( compared with no treatment (very low certainty).
1 finding from 1 review
Short‐term improvement as measured on a continuous scale ( · adults with panic disorder
1 finding from 1 review
Short‐term remission · adults with panic disorder
It is very uncertain whether cognitive behaviour therapy changes short‐term remission ( compared with psychodynamic psychotherapy (very low certainty).
1 finding from 1 review
Short‐term response ( · adults with panic disorder
It is very uncertain whether cognitive behaviour therapy changes short‐term response ( compared with psychodynamic psychotherapy (very low certainty).
1 finding from 1 review
Short‐term dropouts ( · adults with panic disorder
It is very uncertain whether cognitive behaviour therapy changes short‐term dropouts ( compared with psychodynamic psychotherapy (very low certainty).
1 finding from 1 review
Short‐term improvement as measured on a continuous scale ( · adults with panic disorder
1 finding from 1 review
Intervention not reported
Short‐term remission ( · adult patients with panic disorder with or without agoraphobia
1 finding from 1 review
Intervention not reported
Short‐term response ( · adult patients with panic disorder with or without agoraphobia
1 finding from 1 review
Intervention not reported
Short‐term dropouts ( · adult patients with panic disorder with or without agoraphobia
1 finding from 1 review
Short‐term response ( · adults with panic disorder
It is very uncertain whether cognitive behaviour therapy changes short‐term response ( compared with no treatment (very low certainty).
1 finding from 1 review